|28 July 2016|


A new biotech company being launched in Scotland is to lead the fight against a wide range of diseases – including cancer and dementia.

Epidarex Capital today announced the launch of Nodthera Limited – a company based on the world-class research conducted within Selvita, an international drug discovery company. Nodertha will be headquartered in Edinburgh, Scotland’s capital city and is further recognition of the growing strength of the Scottish biotech sector.

Nodthera aims to become a key player in developing inhibitors of a protein complex,  NLRP3 inflammasome, which is implicated in a wide range of diseases that are a substantial burden on modern healthcare systems such as type 2 diabetes, gout, rheumatoid arthritis, Alzheimer’s disease and cancer.

Elizabeth Roper, PhD, a Partner at Epidarex Capital, led the deal and said: “Nodthera Limited has the potential to create first in class small molecule modulators of the NLRP3 inflammasome complex which could be a significant development in the field. Epidarex is delighted to be partnering with Selvita to bring this exciting science to market.”

Krzysztof Brzozka, PhD, Chief Scientific Officer at Selvita, added: “We are confident that Nodthera’s therapeutic approach is exceptional and addresses an important class of intracellular receptors implicated in variety of disorders with unmet medical needs. We’re excited to work with a partner such as Nodthera, who shares our vision and belief that in drug discovery joining forces and cooperation is the key to success.”